Success Metrics

Clinical Success Rate
20.0%

Based on 2 completed trials

Completion Rate
20%(2/10)
Active Trials
0(0%)
Results Posted
400%(8 trials)
Terminated
8(40%)

Phase Distribution

Ph phase_2
6
30%
Ph phase_1
14
70%

Phase Distribution

14

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
14(70.0%)
Phase 2Efficacy & side effects
6(30.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

10.0%

2 of 20 finished

Non-Completion Rate

90.0%

18 ended early

Currently Active

0

trials recruiting

Total Trials

20

all time

Status Distribution
Completed(2)
Terminated(18)

Detailed Status

Withdrawn10
Terminated8
Completed2

Development Timeline

Analytics

Development Status

Total Trials
20
Active
0
Success Rate
20.0%
Most Advanced
Phase 2

Trials by Phase

Phase 114 (70.0%)
Phase 26 (30.0%)

Trials by Status

completed210%
terminated840%
withdrawn1050%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT03169764Phase 1

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03169738Phase 1

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Withdrawn
NCT03169777Phase 1

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn
NCT03175666Phase 1

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn
NCT03574649Phase 2

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn
NCT03554109Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn
NCT03197584Phase 1

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Withdrawn
NCT03197571Phase 1

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03563144Phase 2

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn
NCT03329248Phase 1

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated
NCT03563157Phase 1

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated
NCT03586869Phase 1

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Terminated
NCT03387085Phase 1

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated
NCT03387111Phase 1

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Terminated
NCT03136406Phase 1

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated
NCT03387098Phase 1

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated
NCT03563170Phase 1

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Withdrawn
NCT01322815Phase 2

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI

Terminated
NCT00300950Phase 2

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

Completed
NCT00655161Phase 2

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

Completed

All 20 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
20